CT-0180

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameCT-0180
Drug Alias NameCT0180 humanized anti GPC3 autogenous T Cell injectionCT-0180
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitors
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarsgen Biomedicine (Shanghai) Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A